- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- In appraisal
- Process:
- STA Standard
- ID number:
- 6291
Provisional Schedule
- Committee meeting: 1:
- 06 January 2026
- Expected publication:
- 18 March 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- AbbVie (venetoclax)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Chronic Lymphocytic Leukaemia Support Charity
- Leukaemia Care
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- British Society for Haematology
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- UK CLL Forum
- Associated public health groups
- None
- Comparator companies
- AstraZeneca UK (acalabrutinib) (confidentiality agreement signed, participating)
- Janssen-Cilag (a Johnson & Johnson Innovative Medicine Company) (ibrutinib) (confidentiality agreement signed, participating)
- Pfizer (rituximab) (confidentiality agreement signed, participating)
- Baxter Healthcare (cyclophosphamide) (confidentiality agreement not signed, not participating)
- Celltrion Healthcare UK (rituximab) (confidentiality agreement not signed, not participating)
- Dr. Reddy's Laboratories UK (bendamustine) (confidentiality agreement not signed, not participating)
- Roche Products (obinutuzumab, rituximab) (confidentiality agreement not signed, not participating)
- Sandoz (cyclophosphamide, rituximab) (confidentiality agreement not signed, not participating)
- Sanofi (fludarabine) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating)
- Zentiva (bendamustine) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
- Leukaemia UK
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 May 2025 | Invitation to participate |
| 26 March 2025 - 23 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 April 2024 | Please note that following on from a request received from the company, which was considered and approved by NICE and NHS England - the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-May 2025 when we will write to you about how you can get involved. |
| 15 February 2024 | Please note the draft scope release date is currently TBC and an update will be available in due course |
| 04 January 2024 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual